BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the
Company plans to release its financial results for the twelve months
ended December 31, 2011, on Tuesday, March 13, 2012, after market close.
The Company will host a conference call and audio webcast to discuss its
fourth quarter and year-end financial results, product development
programs and business activities at 4:30 p.m. EDT the same day.
The conference call may be accessed on March 13, 2012 by dialing (877)
224 - 4059 for the U.S. and Canada (passcode: 57985649). The
international dial in number is (706) 902 - 2069, and the same passcode
applies. Participants should dial in 10 minutes prior to the call.
A live webcast of the conference call will be available on the Investor
Relations section of BioMimetic's website at www.biomimetics.com.
The webcast will be archived for at least 30 days following the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company
specializing in the development and commercialization of clinically
proven products to promote the healing of musculoskeletal injuries and
diseases, including therapies for orthopedics, sports medicine and spine
applications. All Augment branded products are based upon recombinant
human platelet-derived growth factor (rhPDGF-BB), which is an engineered
form of PDGF, one of the body's principal agents to stimulate and direct
healing and regeneration. Through the commercialization of this patented
technology, BioMimetic seeks to become the leading company in the field
of regenerative medicine by providing new treatment options for the
repair of bone, cartilage, tendons and ligaments.
BioMimetic received regulatory approval in 2009 and 2011 to market
Augment in Canada, and in Australia for hindfoot and ankle fusion
indications. Augment is pending regulatory decisions in the U.S. and
European Union for similar indications. The Company also markets a bone
graft substitute line of products for orthopedic indications called
Augmatrix Biocomposite Bone Graft.
For further information contact Kearstin Patterson, director of
corporate communications, at 615-236-4419.